Reasons to buy
Each comprehensive report provides unrivalled depth and insight into each complex disease area:
- A groundbreaking compilation of all the major health technology assessments (HTA) and pricing and reimbursement reviews
- Market access roadmaps based on country specific Strategic Insights summarised at the start of each chapter in addition to the Executive Summary
- Authored by writers who have significant experience of clinical development, having brought products to market from phase II, successfully taken products through HTA and pricing and reimbursement and who have been members of HTA bodies
- Independent external validation by payers and KOLs.
To find out more or register your disease area interest, click here
Fill in the fields below and press submit. A member of our team
will respond
shortly.